Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.
OPTI-RET
Gene therapy for retinal dystrophies
Investment: 640k€
Scope: Health
Scientific field(s): Biology and Medicinal Chemistry
Institution(s): Université Paris-Saclay, CNRS, Retina France
Development: Technology to be marketed
#1
Gene therapy targeting a wide range of retinal degenerative diseases
#2
Demonstrated long-lasting neuroprotective effect during maturation
#3
Mature technology with high scientific credibility
USE CASES
- A versatile product that can be used to treat a wide range of degenerative retinal diseases.
- The initial applications relate to degenerative photoreceptor diseases such as retinitis pigmentosa and glaucoma.
APPLICATIONS
- A neuroprotective protein in the retina has been discovered by the project team, thanks to their years of research into the underlying mechanism of action.
- A gene therapy product can effectively induce a neuroprotective effect.
ADVANTAGES
- Effective neuroprotection
- Therapeutic effect with AAVs
- Wide range of applications in degenerative retinal diseases
- The team’s expertise in this field